Skip Navigation


Annals of Oncology Advance Access originally published online on August 13, 2007
Annals of Oncology 2007 18(9):1500-1505; doi:10.1093/annonc/mdm195
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/9/1500    most recent
mdm195v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pisano, C
Right arrow Articles by Zunino, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pisano, C
Right arrow Articles by Zunino, F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

gynecologic tumors

Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models

C Pisano1, L Vesci1, R Foderà1, FF Ferrara1, C Rossi2, M De Cesare3, V Zuco3, G Pratesi3, R Supino3 and F Zunino3,*

1 Research and Development, Sigma-Tau, Pomezia (Rome)
2 Unit of Animal Care and Experimental Models, Consorzio Mario Negri Sud, Santa Maria Imbaro (CH)
3 Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

* Correspondence to: Dr F. Zunino, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy. Tel: +39-02-23902267; Fax: +39-02-23902692; E-mail: franco.zunino{at}istitutotumori.mi.it

Background: The novel adamantyl retinoid ST1926 is a potent inducer of apoptosis in ovarian carcinoma cells. Since the pro-apoptotic effect is associated with activation of p53, in this study we have investigated the efficacy of combination of ST1926 with cisplatin, a DNA-damaging agent that is known to induce p53-dependent apoptosis.

Materials and methods: The efficacy of ST1926 and its combination with cisplatin was evaluated in human ovarian carcinoma models, including resistant tumors.

Results: Oral treatment with ST1926 alone caused a marginal tumor growth inhibition (<50%), but the combination with cisplatin resulted in an improved efficacy, most evident in terms of tumor growth delay without a substantial increase of toxicity. The combination therapy achieved the best effects against the HOC18 ovarian carcinoma tumor, resulting in an appreciable number of animals without evidence of disease at the end of the experiment. In contrast to the marginal effect of ST1926 alone against the subcutaneous-growing tumors, loco-regional (intraperitoneal) treatment achieved a marked increase of survival of animals with ascitic IGROV-1 tumor.

Conclusions: The present results document the efficacy of the combination of cisplatin with ST1926 and provide a rational basis for the design of novel, well-tolerated platinum-based treatment approaches in human ovarian carcinoma.

Key words: atypical retinoids, cisplatin, ovarian carcinoma, ST1926

Received for publication January 23, 2007. Revision received March 30, 2007. Accepted for publication April 12, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

In this issue

Ann Oncol 2007 18: 1427. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
C. Valli, G. Paroni, A. M. Di Francesco, R. Riccardi, M. Tavecchio, E. Erba, A. Boldetti, M. Gianni', M. Fratelli, C. Pisano, et al.
Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity
Mol. Cancer Ther., September 1, 2008; 7(9): 2941 - 2954.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.